pharmaphorum

JUNE 9, 2022

Sanofi has launched a new initiative in its drive to integrate digital technologies throughout its business, setting up an accelerator based in Paris that will serve as the lynchpin of the effort. The accelerator has been set up to “develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI)”, said the drugmaker.

105

105

Pharmacy Friday Pearls

JUNE 9, 2022

Download PDF. Introduction. Steroid use in ARDS has been a highly debated topic around dosing, which steroid, durations, when to initiate therapy. With the emergence of COVID-19, the debate has resurfaced along with numerous trials. The thought behind using steroids in this patient population is to use the anti-inflammatory and anti-proliferative effects of glucocorticoids to mitigate the progression and limit the severity of this inflammatory disease.

Hospitals 40

Hospitals 40

pharmaphorum

JUNE 9, 2022

Antimicrobial resistance (AMR) is an issue of global concern, killing roughly 1.2 million 1 people per year and projected to rise to 10 million people by 2050 2. It occurs when bacterial pathogens adapt over time to develop resistance to traditional antibiotics, resulting in “superbugs” that are near impossible to treat. In order to reduce the global healthcare impact of the evolving AMR situation, companies such as Micreos Pharmaceuticals are taking a novel and highly innovative approach to ant

Chemotherapy 91

Chemotherapy 91

Pharma Manufacturing

JUNE 9, 2022

Fulfilling the promise of CGT will require a carefully cultured talent ecosystem

45

45

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JUNE 9, 2022

The UK’s fertile environment for biotechs specialising in artificial intelligence has generated a new player – Charm Therapeutics – which came out of stealth mode this morning with a $50 million first-round financing. The London-based start-up has been founded by David Baker, head of the Institute of Protein Design at the University of Washington in Seattle, and Laksh Aithani, whose past roles include a couple of years working on the machine learning platform of fellow UK-based AI speciali

78

78

Pharma Times

JUNE 9, 2022

Vital dengue vaccine offers over four years’ protection following successful clinical trial

Vaccines 46

Vaccines 46

Pharma Times

JUNE 9, 2022

Agreement between the two companies includes process development of AAV-based gene therapies

40

40

pharmaphorum

JUNE 9, 2022

Moderna’s new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company’s original Spikevax shot in a head-to-head clinical trial. mRNA-1273.214 stimulated almost twice the neutralising antibody levels against the Omicron strain than Spikevax , with a significantly higher response also seen against other variants of concern, one month after administration, according to the company.

Vaccines 105

Vaccines FDA 105

pharmaphorum

JUNE 9, 2022

Owkin has enticed another big pharma partner with its artificial intelligence-powered clinical development platform, Bristol-Myers Squibb, which is paying $80 million upfront to tap into its expertise. The deal is split between a Series B financing led by BMS and upfront fees, taking the total raised by the Paris, France-based startup to $300 million, and also includes another $100 million in potential milestone payments.

59

59

pharmaphorum

JUNE 9, 2022

Digital health funding has grown exponentially over the last few years and fuelled significant investment. Payers, healthcare professionals (HCPs) and patients recognise the positive impact these digital tools can have either standalone or in conjunction with therapeutic intervention. For instance, earlier last month Pfizer and Sidekick Health launched a new dermatitis app aimed at improving medication management of patients with skin diseases and Akili partnered with Robolox expanding children’

139

139

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA